Transcriptomic profiling of scleroderma monocytes reveals links with cardiovascular complications, implicating Notch and interferon pathways

  • 0Arthritis and Autoimmune Diseases Center, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.

|

|

Summary

This summary is machine-generated.

Systemic sclerosis monocytes show distinct inflammatory profiles linked to organ damage. Elevated interferon activity correlates with cardiac dysfunction, suggesting new therapeutic targets for systemic sclerosis complications.

Area Of Science

  • Immunology
  • Genomics
  • Cardiology

Background

  • Monocytes and macrophages are key drivers of inflammation and fibrosis in systemic sclerosis.
  • Understanding monocyte gene expression is crucial for identifying systemic sclerosis complications and therapeutic targets.

Purpose Of The Study

  • To investigate gene expression profiles of monocytes in systemic sclerosis patients.
  • To explore the relationship between these profiles and disease complications.
  • To identify novel therapeutic targets for systemic sclerosis.

Main Methods

  • Bulk RNA sequencing was performed on monocytes from 48 systemic sclerosis patients and 15 controls.
  • Differential gene expression, hierarchical clustering, and pathway analysis were conducted.
  • Interferon signature score (IFN6) and correlations with clinical features, including global longitudinal strain (GLS), were analyzed.

Main Results

  • Four monocyte gene expression subgroups were identified: two inflammatory and two non-inflammatory.
  • Inflammatory subgroups showed high interferon-related gene expression and were associated with pulmonary hypertension and cardiac involvement.
  • Elevated IFN6 correlated significantly with impaired GLS, and Notch signaling was enriched in genes linked to cardiac dysfunction.

Conclusions

  • A mechanistic link between interferon activity, Notch signaling, and cardiac complications in systemic sclerosis is proposed.
  • These findings offer new insights into systemic sclerosis pathogenesis.
  • Potential novel therapeutic targets for systemic sclerosis have been identified.